UK to offer Oxford-AstraZeneca alternative to under-30s over blood clot concerns

The UK’s medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford-AstraZeneca vaccine due to “evolving evidence” linking it to rare blood clots, even as the European Medicines Agency (EMA) concluded a “possible link” between the vaccine and rare clotting.